Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2018

Open Access 01-12-2018 | Research article

Can deep transcranial magnetic stimulation (DTMS) be used to treat substance use disorders (SUD)? A systematic review

Authors: Karina Karolina Kedzior, Imke Gerkensmeier, Maria Schuchinsky

Published in: BMC Psychiatry | Issue 1/2018

Login to get access

Abstract

Background

Deep transcranial magnetic stimulation (DTMS) is a non-invasive method of stimulating widespread cortical areas and, presumably, deeper neural networks. The current study assessed the effects of DTMS in the treatment of substance use disorders (SUD) using a systematic review.

Methods

Electronic literature search (PsycInfo, Medline until April 2017) identified k = 9 studies (k = 4 randomized-controlled trials, RCTs, with inactive sham and k = 5 open-label studies). DTMS was most commonly applied using high frequency/intensity (10–20 Hz/100–120% of the resting motor threshold, MT) protocols for 10–20 daily sessions in cases with alcohol, nicotine or cocaine use disorders. The outcome measures were craving and dependence (according to standardized scales) or consumption (frequency, abstinence or results of biological assays) at the end of the daily treatment phases and at the last follow-up.

Results

Acute and longer-term (6–12 months) reductions in alcohol craving were observed after 20 sessions (20 Hz, 120% MT) relative to baseline in k = 4 open-label studies with comorbid SUD and major depressive disorder (MDD). In k = 2 RCTs without MDD, alcohol consumption acutely decreased after 10–12 sessions (10–20 Hz, 100–120% MT) relative to baseline or to sham. Alcohol craving was reduced only after higher frequency/intensity DTMS (20 Hz, 120% MT) relative to sham in k = 1 RCT. Nicotine consumption was reduced and abstinence was increased after 13 sessions (10 Hz, 120% MT) and at the 6-month follow-up relative to sham in k = 1 RCT. Cocaine craving was reduced after 12 sessions (15 Hz, 100% MT) and at the 2-month follow-up relative to baseline in k = 1 open-label study while consumption was reduced after 12 sessions (10 Hz, 100% MT) relative to baseline but not to sham in k = 1 RCT.

Conclusions

High-frequency DTMS may be effective at treating some SUD both acutely and in the longer-term. Large RCTs with inactive sham are required to determine the efficacy and the optimal stimulation parameters of DTMS for the treatment of SUD.
Literature
1.
Zangen A, Roth Y, Voller B, Hallett M. Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil. Clin Neurophysiol. 2005;116:775–9.CrossRefPubMed
2.
Kedzior KK, Gellersen H, Brachetti A, Berlim MT. Deep transcranial magnetic stimulation (DTMS) in the treatment of major depression: an exploratory systematic review and meta-analysis. J Affect Disord. 2015;187:73–83.CrossRefPubMed
3.
Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015;14:64–73.CrossRefPubMedPubMedCentral
4.
Kedzior KK, Gellersen H, Roth Y, Zangen A. Acute reduction in anxiety after deep transcranial magnetic stimulation (DTMS) in unipolar major depression- a systematic review and meta-analysis. Psychiatry Res. 2015;230:971–4.CrossRefPubMed
5.
Kedzior KK, Gierke L, Gellersen HM, Berlim MT. Cognitive functioning and deep transcranial magnetic stimulation (DTMS) in major psychiatric disorders: a systematic review. J Psychiatr Res. 2016;75:107–15.CrossRefPubMed
6.
Levkovitz Y, Harel EV, Roth Y, Braw Y, Most D, Katz LN, Sheer A, Gersner R, Zangen A. Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of antidepressant and cognitive effects in depressive patients. Brain Stimul. 2009;2:188–200.CrossRefPubMed
7.
Kedzior KK, Gellersen HM. Clinical application of deep transcranial magnetic stimulation (DTMS) in neuropsychiatric disorders: a systematic literature review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2017;267:34.
8.
Tendler A, Barnea Ygael N, Roth Y, Zangen A. Deep transcranial magnetic stimulation (dTMS) - beyond depression. Expert Rev Med Devices. 2016;13:987–1000.CrossRefPubMed
9.
Hadar A, Zangen A. Brain stimulation as a novel technique for craving management and the treatment of addiction. In: Wilson SJ, editor. The Wiley handbook on the cognitive neuroscience of addiction. USA: Wiley & Sons, Ltd.; 2015.
10.
Rapinesi C, Kotzalidis GD, Ferracuti S, Girardi N, Zangen A, Sani G, Raccah RN, Girardi P, Pompili M, Del Casale A. Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex in depressive episodes of patients with major depressive disorder, bipolar disorder I, and major depressive with alcohol use disorders. Neurosci Lett. 2018;671:128–32.CrossRefPubMed
11.
Diana M, Raij T, Melis M, Nummenmaa A, Leggio L, Bonci A. Rehabilitating the addicted brain with transcranial magnetic stimulation. Nat Rev Neurosci. 2017;18:685–93.CrossRefPubMed
12.
Parazzini M, Fiocchi S, Chiaramello E, Roth Y, Zangen A, Ravazzani P. Electric field estimation of deep transcranial magnetic stimulation clinically used for the treatment of neuropsychiatric disorders in anatomical head models. Med Eng Phys. 2017;43:30–8.CrossRefPubMed
13.
Roth Y, Pell GS, Chistyakov AV, Sinai A, Zangen A, Zaaroor M. Motor cortex activation by H-coil and figure-8 coil at different depths. Combined motor threshold and electric field distribution study. Clin Neurophysiol. 2014;125:336–43.CrossRefPubMed
14.
Gorelick DA, Zangen A, George MS. Transcranial magnetic stimulation (TMS) in the treatment of substance addiction. Ann N Y Acad Sci. 2014;1327:79–93.PubMedPubMedCentral
15.
Karoly HC, YorkWilliams SL, Hutchison KE. Clinical neuroscience of addiction: similarities and differences between alcohol and other drugs. Alcohol Clin Exp Res. 2015;39:2073–84.CrossRefPubMed
16.
Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral
17.
Rapinesi C, Kotzalidis GD, Serata D, Del Casale A, Bersani FS, Solfanelli A, Scatena P, Raccah RN, Brugnoli R, Digiacomantonio V, Carbonetti P, Fensore C, Tatarelli R, Angeletti G, Ferracuti S, Girardi P. Efficacy of add-on deep transcranial magnetic stimulation in comorbid alcohol dependence and dysthymic disorder: three case reports. Prim Care Companion CNS Disord. 2013;15 https://​doi.​org/​10.​4088/​PCC.​4012m01438.
18.
Dinur-Klein L, Dannon P, Hadar A, Rosenberg O, Roth Y, Kotler M, Zangen A. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry. 2014;76:742–9.CrossRefPubMed
19.
Rapinesi C, Kotzalidis GD, Scatena P, Del Casale A, Janiri D, Callovini G, Piacentino D, Serata D, Raccah RN, Brugnoli R, Digiacomantonio V, Mascioli F, Ferri VR, Ferracuti S, Pompili M, De Pisa E, Di Pietro S, Zangen A, Angeletti G, Girardi P. Alcohol and suicidality: could deep transcranial magnetic stimulation (dTMS) be a possible treatment? Psychiatr Danub. 2014;26:281–4.PubMed
20.
Ceccanti M, Inghilleri M, Attilia ML, Raccah R, Fiore M, Zangen A, Ceccanti M. Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation. A pilot study. Can J Physiol Pharmacol. 2015;93:283–90.CrossRefPubMed
21.
Girardi P, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V, Ferri VR, Ferracuti S, Zangen A, Angeletti G. Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: a comparison with standard treatment. World J Biol Psychiatry. 2015;16:66–73.CrossRefPubMed
22.
Rapinesi C, Curto M, Kotzalidis GD, Del Casale A, Serata D, Ferri VR, Di Pietro S, Scatena P, Bersani FS, Raccah RN, Digiacomantonio V, Ferracuti S, Bersani G, Zangen A, Angeletti G, Girardi P. Antidepressant effectiveness of deep transcranial magnetic stimulation (dTMS) in patients with major depressive disorder (MDD) with or without alcohol use disorders (AUDs): a 6-month, open label, follow-up study. J Affect Disord. 2015;174:57–63.CrossRefPubMed
23.
Rapinesi C, Del Casale A, Di Pietro S, Ferri V, Piacentino D, Sani G, Raccah R, Zangen A, Ferracuti S, Vento A, Angeletti G, Brugnoli R, Kotzalidis G, Girardi P. Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex reduces cocaine craving in patients with cocaine use disorder. Neurosci Lett. 2016;629:43–7.CrossRefPubMed
24.
Bolloni C, Panella R, Pedetti M, Frascella AG, Gambelunghe C, Piccoli T, Maniaci G, Brancato A, Cannizzaro C, Diana M. Bilateral transcranial magnetic stimulation of the prefrontal cortex reduces cocaine intake: a pilot study. Front Psychiatry. 2016;7:133.CrossRefPubMedPubMedCentral
25.
Addolorato G, Antonelli M, Cocciolillo F, Vassallo GA, Tarli C, Sestito L, Mirijello A, Ferrulli A, Pizzuto DA, Camardese G, Miceli A, Diana M, Giordano A, Gasbarrini A, Di Giuda D. Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake. Eur Neuropsychopharmacol. 2017;27:450–61.CrossRefPubMed
26.
27.
Hanlon CA, Dowdle LT, Austelle CW, DeVries W, Mithoefer O, Badran BW, George MS. What goes up, can come down: novel brain stimulation paradigms may attenuate craving and craving-related neural circuitry in substance dependent individuals. Brain Res. 2015;1628:199–209.CrossRefPubMedPubMedCentral
28.
Liu Q, Shen Y, Cao X, Li Y, Chen Y, Yang W, Yuan T-F. Either at left or right, both high and low frequency rTMS of dorsolateral prefrontal cortex decreases cue induced craving for methamphetamine. Am J Addict. 2017;26:776–9.CrossRefPubMed
29.
Fitzgerald P. rTMS in depression: is more always better? Clin Neurophysiol. 2017;128:e3.CrossRef
30.
Kedzior KK, Azorina V, Reitz SK. More female patients and fewer stimuli per session are associated with the short-term antidepressant properties of repetitive transcranial magnetic stimulation (rTMS): a meta-analysis of 54 sham-controlled studies published between 1997-2013. Neuropsychiatr Dis Treat. 2014;10:727–56.CrossRefPubMedPubMedCentral
31.
Feil J, Zangen A. Brain stimulation in the study and treatment of addiction. Neurosci Biobehav Rev. 2010;34:559–74.CrossRefPubMed
32.
Salling, MC, Martinez, D. Brain stimulation in addiction. Neuropsychopharmacology. 2016;41:2798–2809.
33.
Grall-Bronnec M, Sauvaget A. The use of repetitive transcranial magnetic stimulation for modulating craving and addictive behaviours: a critical literature review of efficacy, technical and methodological considerations. Neurosci Biobehav Rev. 2014;47:592–613.CrossRefPubMed
34.
Hone-Blanchet A, Ciraulo DA, Pascual-Leone A, Fecteau S. Noninvasive brain stimulation to suppress craving in substance use disorders: review of human evidence and methodological considerations for future work. Neurosci Biobehav Rev. 2015;59:184–200.CrossRefPubMedPubMedCentral
35.
Jansen JM, Daams JG, Koeter MW, Veltman DJ, van den Brink W, Goudriaan AE. Effects of non-invasive neurostimulation on craving: a meta-analysis. Neurosci Biobehav Rev. 2013;37:2472–80.CrossRefPubMed
36.
37.
Schmittwilken L, Schuchinsky M, Kedzior K. Neurobiological mechanisms of deep transcranial magnetic stimulation (DTMS): a systematic review. Brain Stimul. 2017;10:379.CrossRef
38.
Barr MS, George TP. Deep repetitive transcranial magnetic stimulation for smoking cessation: is going deeper better? Biol Psychiatry. 2014;76:678–80.CrossRefPubMed
39.
Kedzior K, Gerkensmeier I, Schuchinsky M. How deep is the deep transcranial magnetic stimulation (DTMS)? Putative stimulation of reward pathways in substance use disorders: a systematic review and meta-analysis. Brain Stimul. 2017;10:355.
40.
Kedzior K, Badcock J, Martin-Iverson M. Validity and consistency of self-reports regarding substance use in general research volunteers, including regular cannabis users and schizophrenia patients. Subst Use Misuse. 2006;41:743–50.CrossRefPubMed
41.
Ross HE, Gavin DR, Skinner HA. Diagnostic validity of the MAST and the alcohol dependence scale in the assessment of DSM-III alcohol disorders. J Stud Alcohol. 1990;51:506–13.CrossRefPubMed
42.
Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom tolerance questionnaire. J Behav Med. 1989;12:159–82.CrossRefPubMed
43.
44.
Anton RF, Moak DH, Latham P. The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19:92–9.CrossRefPubMed
45.
Heishman SJ, Singleton EG, Pickworth WB. Reliability and validity of a short form of the tobacco craving questionnaire. Nicotine Tob Res. 2008;10:643–51.CrossRefPubMedPubMedCentral
46.
Vakili S, Sobell LC, Sobell MB, Simco ER, Agrawal S. Using the timeline Followback to determine time windows representative of annual alcohol consumption with problem drinkers. Addict Behav. 2008;33:1123–30.CrossRefPubMed
47.
McMillan DE, Gilmore-Thomas K. Stability of opioid craving over time as measured by visual analog scales. Drug Alcohol Depend. 1996;40:235–9.CrossRefPubMed
Metadata
Title
Can deep transcranial magnetic stimulation (DTMS) be used to treat substance use disorders (SUD)? A systematic review
Authors
Karina Karolina Kedzior
Imke Gerkensmeier
Maria Schuchinsky
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2018
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-018-1704-0

Other articles of this Issue 1/2018

BMC Psychiatry 1/2018 Go to the issue

Research article

Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder

Case report

Heterozygous deletion of SCN2A and SCN3A in a patient with autism spectrum disorder and Tourette syndrome: a case report

Research article

Mental health outcomes among Arab refugees, immigrants, and U.S. born Arab Americans in Southeast Michigan: a cross-sectional study

Research article

Depressive disorders among patients with gastric cancer in Taiwan: a nationwide population-based study

Research article

Perceived parental support in childhood and adolescence and suicidal ideation in young adults: a cross-sectional analysis of the i-Share study

Research article

Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-term psychosis